posttraumatic stress disorder, PTSD, trauma posttraumatic stress disorder, PTSD, trauma
Conditions
Interventions
Half of initially non-responsive patients will be treated with the non-trauma-focused intervention interpersonal therapy (IPT) in phase 2 of the study. The first and second phases will offer the traum
Markowitz, 2019). PTSD following a traumatic life event produces social withdrawal and a blunted, inhibited emotional life, disrupting interpersonal functioning. IPT helps benumbed patients recognize
Arntz, 2017).
- In EMDR, patients are distracted from the traumatic memories by a dual attention task, usually using eye movements. This study will use a protocolled EMDR treatment for PTSD (De Jongh
Ten Broeke, 2019).
Sponsors
Dimence Groep
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: - Adults between the ages of 18 and 65 who were classified at intake with a primary diagnosis of PTSD (based on the DSM-5 criteria). - Adults who are willing to participate in the research (informed consent).
Exclusion criteria
Exclusion criteria: - Insufficient mastery of the Dutch language. - Patients who cannot follow the treatment protocol (for example due to long-term absence) are excluded from the study. - Patients who use medication that is not stable. If properly adjusted to the last prescribed medication, the medication is continued as advised by the doctor and preferably not changed during the treatment, unless necessary due to side effects, crisis, et cetera. - Patients who have already received a proven effective form of trauma-focused treatment for PTSD earlier in the past year (of a sufficiently long duration according to the guidelines of the standard of care and sufficiently well implemented to be effective). - Patients with severe suicidality, which requires acute intervention and the structural addition of additional treatment interventions (such as hospitalization). - Patients with a (mild) intellectual disability. - Patients with a serious addiction as a comorbid problem. - Patients with an acute mania or a psychotic state.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measure for treatment effectiveness in both phases is PTSD symptom reduction measured with the PTSD Checklist for the DSM-5 (PCL-5; Boeschoten, Bakker, Jongedijk, & Olff, 2014). The PCL-5 is administered at baseline and repeated weekly. The week 8 assessment serves as the endpoint of phase 1 and the start measurement of phase 2. The PCL-5 is also administered weekly in phase 2. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome measures are the CAPS-5, ITV, HADS, MHC-SF and PNEP. In addition, we shall measure variables to investigate generic predictors of treatment success and specific moderators. Based on the literature, it appears that the following variables may affect outcome. Further, we have added several instruments to match those that Wibbelink et al. (2021) use in their research in order to be able to collaborate in future data analyses (PAI analysis). * Demographic variables: age, gender, education, employment, marital status, ethnicity/race, medication use, treatment history. * Mini-SCAN, LEC-5, CTQ-SF, ECR-RS, SCL-90 hostility subscale, BEAQ, IAPT, PTCI, TRGI, TRSI, WAV-12 and an expectancy rating for both patients and therapists. | — |
Countries
Netherlands
Contacts
Public ContactM Schaufeli
Dimence Groep
Outcome results
None listed